Gyre Therapeutics (GYRE) FCF Margin (2010 - 2026)

Gyre Therapeutics (GYRE) has 16 years of FCF Margin data on file, last reported at 13.42% in Q1 2026.

• FCF Margin for Q1 2026 came in at 13.42%, up 1456.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 2.63% (up 1144.0% YoY), and the FY2025 annual result was 0.16%, up 547.0% from the prior year.
• FCF Margin climbed to 13.42% in Q1 2026 per GYRE's latest filing, from 15.44% in the prior quarter.
• Over five years, FCF Margin peaked at 41.67% in Q4 2022 and troughed at 1517.63% in Q1 2022.
• A 5-year average of 94.64% and a median of 7.0% in 2025 frame the typical range for FCF Margin.
• On a YoY basis, FCF Margin climbed as much as 155243 bps in 2023 and fell as far as 3786 bps in 2023.
• A 5-year view of FCF Margin shows it stood at 41.67% in 2022, then slumped by 91 bps to 3.82% in 2023, then plunged by 353 bps to 9.66% in 2024, then tumbled by 60 bps to 15.44% in 2025, then surged by 187 bps to 13.42% in 2026.
• Business Quant data shows GYRE's FCF Margin at 13.42% in Q1 2026, 15.44% in Q4 2025, and 12.86% in Q3 2025.